Registration Webcast Header

LivaNova 2021 Investor Day

Already Registered?

Log in Now


Event Date: December 7, 2021
Start Time: 9:00 am EST
Executive leadership will share the LivaNova long-range business plan to maximize growth and shareholder value. Senior leadership, accompanied by key opinion leader clinicians, will provide overviews on the Company’s franchises and strategic pipeline initiatives. The leadership team will also be available for Q&A sessions.


Damien McDonald

Chief Executive Officer

Damien McDonald is the Chief Executive Officer of LivaNova. Previously, Mr. McDonald served as Chief Operating Officer of LivaNova. Prior to that, he was Group Executive and Corporate Vice President at Danaher Corporation where he led a $1.5-billion group of dental consumables companies. Earlier in his tenure, he was Group President of Kerr where he and his team focused on building a strong research and development pipeline while improving operational performance utilizing the Danaher Business System. Additionally, Mr. McDonald previously led Zimmer’s spine division where he demonstrated his leadership skills, attracting a strong executive team that created a growth trajectory for the business unit. Earlier in his career, he worked with J&J’s Medical Device Franchises, including Ethicon, where he led marketing of the $2.5-billion medical device unit. Mr. McDonald earned an MBA at the Institute for Management Development (IMD) in Lausanne, Switzerland, along with a Master of Science in International Economics from the University of Wales, U.K. He also holds a Bachelor of Economics degree and Bachelor of Pharmacy degree, both from the University of Queensland, Australia.

Alex Shvartsburg

Chief Financial Officer

Alex Shvartsburg is the Chief Financial Officer of LivaNova. From November 2020 to July 2021, Mr. Shvartsburg served as the interim Chief Financial Officer of LivaNova. Prior to his appointment to the role, he led the LivaNova Corporate Financial Planning and Analysis group and was the International Region CFO. Before joining LivaNova in 2017, Mr. Shvartsburg was CFO and Chief Operating Officer of Caligor, a private equity-backed clinical services organization, where he was responsible for Finance, Operations, Human Resources and Information Technology functions. Before that, he held finance leadership roles including CFO of the Genetic Sciences division at Thermo Fisher Scientific, Senior Finance Director M&A at Life Technologies, and for over 20 years, Mr. Shvartsburg held a series of finance roles of increasing responsibility within Johnson & Johnson. Mr. Shvartsburg earned a Bachelor of Science degree in Accounting from Drexel University and a Master of Business Administration from LaSalle University. He is a Certified Management Accountant.

Matthew Dodds

Senior Vice President, Corporate Development

Mr. Matthew Dodds currently serves as LivaNova’s Senior Vice President of Corporate Development, Investor Relations, and IT. Prior to joining LivaNova, Matthew Dodds served as Vice President, Strategic Planning at Johnson & Johnson (J&J) Medical Devices. Mr. Dodds joined J&J in 2015 after a 20-year career as an equity research analyst covering the Medical Supplies and Technology industry. He was the Sector Head of the Americas Health Care team at Citigroup. Previously, Mr. Dodds was a Managing Director at SG Cowen and an Executive Director at UBS Warburg as the senior analyst covering Medical Supplies & Technology. Dodds also worked in the Equity Research departments at Kidder Peabody and PaineWebber. Mr. Dodds earned a Bachelor of Science in industrial management from Carnegie Mellon University.

Chris Hartman

General Manager of Epilepsy Sales and Marketing for North America

Mr. Chris Hartman serves as LivaNova’s General Manager of Epilepsy, Sales and Marketing for North America. Mr. Hartman joined LivaNova mid last year and is responsible for leading all existing commercial initiatives and delivering new VNS Therapy for Epilepsy strategies to benefit patients. Mr. Hartman has more than 23 years of medical device experience at Stryker, Baxter and Boston Scientific where he held multiple senior commercial roles and was directly engaged in building device therapy markets in heart failure and acute ischemic stroke. Mr. Hartman earned a Master of Business Administration from Northwestern University Kellogg School of Management and holds a Bachelor of Arts in Economics from the University of Michigan.

Rich Wintersteller

Vice President, General Manager of Cardiovascular North America

Mr. Rich Wintersteller is currently Vice President, General Manager, Sales and Marketing Cardiovascular North America at LivaNova. Mr. Wintersteller joined LivaNova in 2017 and is accountable for all commercial functions driving the Cardiovascular business and leads the transformative shift in commercial excellence across the Cardiopulmonary and Advanced Circulatory Support franchises. Prior to this, Mr. Wintersteller served as Vice President Strategic Accounts and Global Professional Education at Kavo Kerr, a Danaher Company. He was responsible for driving growth in the DSO segment and leading a coordinated global professional education effort across a $1.8B product platform. Mr. Wintersteller also served as Vice President, US Sales, Ethicon Products, a Johnson and Johnson Company and was a member of the Ethicon US Management Board. He had responsibility for the company’s $1B+ Wound Closure business and oversight of the company’s 350-person Sales Organization. During his tenure he had responsibility for developing and implementing the go to market model and guiding the business to growth while maintaining market leadership. Mr. Wintersteller began his medical device in career at Johnson & Johnson in 1992. He held increasing roles of responsibility in the areas of Sales, Corporate Accounts, Product Marketing, Product Marketing Management and Senior Sales Management. Mr. Wintersteller earned a Bachelor of Science degree in Business Administration from Bowling Green State University.

Travis Deschamps

Vice President and General Manager of ACS

Mr. Travis Deschamps serves as LivaNova’s Vice President and General Manager of Advanced Circulatory Support (ACS). He joins us from TandemLife where he previously served as the Chief Operating Officer successfully led management through a 5-year strategic plan to renew the maturing business, which ultimately resulted in the 2018 acquisition by LivaNova. Between 2010 and 2015, Mr. Deschamps held a series of marketing managerial roles within TandemLife where he was responsible for developing and commercializing multiple breakthrough products and three new product lines including ProtekDuo, TandemLung, and TandemLife. Earlier in his career, Mr. Deschamps held several product management roles of increasing responsibility at Bayer Healthcare within the MEDRAD Interventional Division. Before this, Mr. Deschamps was a project manager and consultant at The Hill Group, Inc., a privately held provider of management counsel, specializing in strategy, operations, and measurement. Mr. Deschamps earned a Master of Business Administration from Carnegie Mellon University and holds a Bachelor of Science in Biology from the University of Notre Dame.

Jonathan Walker

U.S. General Manager and Global Vice President of DTD

Mr. Jonathan Walker serves as the U.S. General Manager and Global Vice President of LivaNova’s Difficult-To-Treat Depression business. Mr. Walker is a senior pharmaceutical executive with broad knowledge across therapeutic areas including Oncology, Cardiovascular, Respiratory, and Neuroscience. He has worked for companies including Merck, Bristol-Myers, AstraZeneca and Amgen to drive company critical strategic initiatives both nationally and globally including leading, at AstraZeneca, the multibillion-dollar SERQUEL Franchise in Schizophrenia, Bipolar Disorder and Major Depressive Disorder. Mr. Walker earned a Bachelor of Science in Molecular Biophysics from the University of Leeds.

Bruce H. KenKnight

Vice President of Heart Failure

Bruce H. KenKnight, PhD is Vice President LivaNova’s Heart Failure Program, a strategic initiative started with legacy Cyberonics in 2011 that sought to expand the utility of VNS applications beyond epilepsy. Bruce has over 35 years of experience developing and managing research and technology development programs in start-ups, mid-cap and large cap medical device companies. Prior to joining LivaNova, Bruce served in various roles of increasing responsibility for 20 years at Guidant Corp, acquired by Boston Scientific. Bruce provided voluntary service as an Adjunct Professor of Biomedical Engineering at the University of Minnesota and established and coordinated several courses (Senior Capstone Design, Cardiovascular Devices). Bruce received the Albert Einstein Award for Outstanding Achievement in Life Sciences (2006), was named a Fellow in the College of Fellows of the American Institute for Medical and Biomedical Engineering (2007) and the Distinguished Alumni Award, University of Minnesota (2016). Bruce is named as an inventor on >500 U.S. and international patents and is an author of over 200 peer-reviewed publications in the fields of cardiac electrophysiology, heart failure and neuromodulation. A native of Minnesota, Bruce received the Bachelor of Science degree in mechanical engineering, Master of Science and PhD degrees in biomedical engineering from the College of Science & Engineering at the University of Minnesota.

Lorenzo DiCarlo

Vice President of Medical Affairs

Dr. Lorenzo DiCarlo is currently Vice-President of Medical Affairs—Heart Failure at LivaNova PLC after serving previously in global roles for clinical and medical affairs at Guidant Corporation (now Boston Scientific), Pfizer, and Proteus Digital Health. He has led the successful clinical development of pharmaceuticals and medical devices for heart failure and other cardiovascular disorders, and the incorporation of an ingestible sensor with approved medicinals for use in cardiovascular and other therapeutic areas. Dr. DiCarlo graduated from Tufts University School of Medicine, and completed his internal medicine residency at the Hospital of the University of Pennsylvania with subsequent subspecialty training in cardiology, heart failure, and cardiac rhythm management at the University of California, San Francisco. He has served on the faculties of the University of Michigan School of Medicine and UM School of Computer Science and Electrical Engineering, and the executive steering committees of several multi-center clinical cardiovascular studies. He holds multiple patents and is an author of more than 250 peer-reviewed articles and scientific abstracts.

John Webb

Vice President of Sleep Apnea

Mr. John Webb currently serves as LivaNova’s Vice President of Sleep Apnea. Mr. Webb is primarily responsible for building Sleep Apnea therapy awareness and market development with KOLs and physicians, building clinical evidence on the safety and efficacy of the therapy, influencing the product roadmap and leading upstream activities, driving regulatory approvals in key countries, and building an organization to support the successful global launch of the therapy. John comes to us with experience in various product management and marketing roles with Procter and Gamble, Toyota Motor Corporation, and Edwards Lifesciences. Prior to joining LivaNova in 2018, he served as the Vice President of Marketing at the Masimo Corporation overseeing all global marketing activities. In addition, he served as a Company Commander in the United States Army. Mr. Webb earned a Bachelor of Science in Operations Research and Systems Engineering from the United States Military Academy at West Point and a Master of Science in both Management and Engineering from the Sloan School and School of Engineering at the Massachusetts Institute of Technology. Mr. Webb also holds a Master of Business Administration from The Kelley School of Business at Indiana University and a Master of Science in Systems Engineering from the University of Virginia.

Register Today

First Name
Last Name
Email Address
Job Title
Phone Number